We are live on ! Find out more
AVM

Arch Venture Management Portfolio holdings

AUM $677M
1-Year Est. Return 322.07%
This Fund
S&P 500
This Quarter Est. Return
-17.29%
1 Year Est. Return
+322.07%
3 Year Est. Return
+208.96%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$20M
AUM Growth
-$9.69M
Cap. Flow
-$5.64M
Cap. Flow %
-28.13%
Top 10 Hldgs %
100%
Holding
4
New
–
Increased
–
Reduced
1
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
KURA icon
Kura Oncology
KURA
+$3.36M
2
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$2.27M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RUBY
1
DELISTED
Rubius Therapeutics, Inc
RUBY
$13.1M 65.49%
2,618,351
– –
CHMA
2
DELISTED
Chiasma, Inc. Common Stock
CHMA
$5.15M 25.69%
1,196,776
– –
SYRS
3
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$1.77M 8.83%
20,000
-20,000
-50% -$2.27M
KURA icon
4
Kura Oncology
KURA
$928M
– –
-206,307
Closed -$3.36M

Similar funds

NI
Noked Israel Ramat Hasharon, Israel $677M AUM 69.37% 1-Year Est. Return
MMPW
Mitchell McLeod Pugh & Williams Mobile, Alabama $678M AUM 23.02% 1-Year Est. Return
JC
JBF Capital Aspen, Colorado $676M AUM 24.74% 1-Year Est. Return
NCM
Noesis Capital Mangement Boca Raton, Florida $676M AUM 34.17% 1-Year Est. Return
TWM
Topsail Wealth Management Charlotte, North Carolina $678M AUM 13.87% 1-Year Est. Return
DLIC
Daido Life Insurance Company Osaka, Japan $678M AUM 16.09% 1-Year Est. Return
REAM
Ripple Effect Asset Management New York $679M AUM 81.6% 1-Year Est. Return
MCO
MAK Capital One New York $679M AUM 29.02% 1-Year Est. Return

Arch Venture Management's Q3 2020 Portfolio in Review

As of Q3 2020, Arch Venture Management held 4 positions worth $20M, down 33% from $29.7M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Arch Venture Management withdrew a net $5.64M in Q3 2020, closing 1 position and reducing 1 holding. Its most notable exit was Kura Oncology, an estimated $3.36M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • Arch Venture Management's biggest Q3 2020 reduction was Syros Pharmaceuticals, Inc. Common Stock, cutting an estimated $2.27M.
  • Arch Venture Management fully exited Kura Oncology in Q3 2020, selling an estimated $3.36M.
  • Arch Venture Management's ten largest holdings make up 100% of its $20M portfolio in Q3 2020.
  • Arch Venture Management opened 0 new positions and closed 1 in Q3 2020.
  • Arch Venture Management's portfolio value fell 33% quarter-over-quarter to $20M.

Based on Arch Venture Management's 13F filing for Q3 2020, filed 16 Nov 2020.